<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1993">
  <stage>Registered</stage>
  <submitdate>3/06/2008</submitdate>
  <approvaldate>3/06/2008</approvaldate>
  <nctid>NCT00690703</nctid>
  <trial_identification>
    <studytitle>Radiofrequency Ablation of Pulmonary Tumors Response Evaluation</studytitle>
    <scientifictitle>Radiofrequency Ablation of Pulmonary Tumors Response Evaluation: a Prospective, Intention-to-Treat, Multicenter Clinical Trial</scientifictitle>
    <utrn />
    <trialacronym>RAPTURE</trialacronym>
    <secondaryid>102-00</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Non Small Cell Lung Cancer</healthcondition>
    <healthcondition>Pulmonary Metastases</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Non small cell</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Mesothelioma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Small cell</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - RF ablation (Rita Medical Systems Model 1500x)

Experimental: 1 - Treatment


Treatment: devices: RF ablation (Rita Medical Systems Model 1500x)
computed tomography-guided RF ablation with an expandable electrode needle

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>technical success</outcome>
      <timepoint>immediate</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>complications</outcome>
      <timepoint>30 days</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>pulmonary function</outcome>
      <timepoint>2 years</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>tumor response</outcome>
      <timepoint>1 years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>overall survival</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>cancer-specific survival</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>quality of life</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. adult (&gt; 18 years) male or female patient

          2. patient has biopsy-proven NSCLC or lung metastasis

          3. patient has been rejected for surgery and has been considered unfit for radiation
             therapy or chemotherapy

          4. patient has as many as 3 tumors per lung, each 3.5 cm or smaller in greatest diameter,
             by CT scan

          5. tumors are located at least 1 cm from trachea; main bronchi; esophagus; aorta; aortic
             arch branches; pulmonary artery; and heart

          6. tumors are accessible by percutaneous route

          7. patient has Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

          8. patient has platelet count &gt; 100 x 109 /L and international normalized ratio = 1.5

          9. patient has signed written informed consent prior to any study specific procedures.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. patient has undergone previous pneumonectomy

          2. patient is considered at high-risk for RF ablation due to major co-morbid medical
             conditions

          3. patient has more than 3 tumors / lung

          4. patient has at least one tumor &gt; 3.5 in greatest diameter

          5. tumor is associated with atelectasis or obstructive pneumonitis

          6. patient has renal failure requiring hemodialysis or peritoneal dialysis

          7. patient has active clinically serious infection

          8. patient has history of organ allograft

          9. patient has history of substance abuse or any medical, psychological or social
             conditions that may interfere with his / her participation in the study or evaluation
             of the study results

         10. patient is pregnant or breast-feeding

         11. patient has ECOG performance status &gt; 2

         12. patient has platelet count = 100 x 109 /L or international normalized ratio &gt; 1.5.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2001</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>106</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/12/2007</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>University of New South Wales - Sydney</hospital>
    <postcode>NSW 2052 - Sydney</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Essen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Muenchen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Candiolo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Pisa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Angiodynamics, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study hypothesis is that the radiofrequency (RF) ablation is a safe and effective
      treatment for malignant lung tumors.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00690703</trialwebsite>
    <publication>Lencioni R, Cioni D, Crocetti L, Franchini C, Pina CD, Lera J, Bartolozzi C. Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology. 2005 Mar;234(3):961-7. Epub 2005 Jan 21.
Tateishi R, Shiina S, Teratani T, Obi S, Sato S, Koike Y, Fujishima T, Yoshida H, Kawabe T, Omata M. Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer. 2005 Mar 15;103(6):1201-9.
Miao Y, Ni Y, Bosmans H, Yu J, Vaninbroukx J, Dymarkowski S, Zhang H, Marchal G. Radiofrequency ablation for eradication of pulmonary tumor in rabbits. J Surg Res. 2001 Aug;99(2):265-71.
Pennathur A, Luketich JD, Abbas G, Chen M, Fernando HC, Gooding WE, Schuchert MJ, Gilbert S, Christie NA, Landreneau RJ. Radiofrequency ablation for the treatment of stage I non-small cell lung cancer in high-risk patients. J Thorac Cardiovasc Surg. 2007 Oct;134(4):857-64. Epub 2007 Aug 29.
Simon CJ, Dupuy DE, DiPetrillo TA, Safran HP, Grieco CA, Ng T, Mayo-Smith WW. Pulmonary radiofrequency ablation: long-term safety and efficacy in 153 patients. Radiology. 2007 Apr;243(1):268-75.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Riccardo Lencioni, MD</name>
      <address>University of Pisa, Pisa, Italy</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>